News Drug Development PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518October 18, 2022 | 4 min read Twitter LinkedIn Facebook Email Print PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD tria...
Analogous to the SMA drug from our splicing platform, this trial is anticipated to establish the appropriate PTC518 dose that reduces HTT protein levels. We believe that the convenient oral administration of PTC518 has the potential to change th...
A Drug Safety Monitoring Board will undertake an unblinded review of safety data in Parts A and B and provide a recommendation on when Part C (20 mg PTC518) can be initiated.Brian BeersAmy-Lee BredlauAnu BhattacharyyaAllan Kristensen
(risdiplam), andPTChas leveraged the extensive learnings from theSMAprogram to broaden the platform to support discovery programs across numerous therapeutic areas includingneurodegenerativedisease, oncology and metabolism.PTChas also developed a ...
US enrollment for the phase 2 PIVOT-HD trial (NCT05358717) assessing PTC Therapeutics investigational agent PTC518 in patients with Huntington disease (HD) has been paused, according to the company, as the FDA continues to seek more data about the drug. Although stopped in the US, the stu...
“PTC518 is the only orally bioavailable small molecule therapeutics that was identified to selectively and specifically modulate Huntington's disease splicing to reduce huntingtin protein. Analogous to the SMA drug from our splicing platform, this trial is anticipated to establish the appropriate PTC518...